Manifestations of viral infections can differ between women and men 1 , and marked sex differences have been described in the course of HIV-1 disease. HIV-1-infected women tend to have lower viral loads early in HIV-1 infection but progress faster to AIDS for a given viral load than men 2-7 . Here we show substantial sex differences in the response of plasmacytoid dendritic cells (pDCs) to HIV-1. pDCs derived from women produce markedly more interferon-a (IFN-a) in response to HIV-1-encoded Toll-like receptor 7 (TLR7) ligands than pDCs derived from men, resulting in stronger secondary activation of CD8 + T cells. In line with these in vitro studies, treatment-naive women chronically infected with HIV-1 had considerably higher levels of CD8 + T cell activation than men after adjusting for viral load. These data show that sex differences in TLRmediated activation of pDCs may account for higher immune activation in women compared to men at a given HIV-1 viral load and provide a mechanism by which the same level of viral replication might result in faster HIV-1 disease progression in women compared to men. Modulation of the TLR7 pathway in pDCs may therefore represent a new approach to reduce HIV-1-associated pathology.
Manifestations of viral infections can differ between women and men 1 , and marked sex differences have been described in the course of HIV-1 disease. HIV-1-infected women tend to have lower viral loads early in HIV-1 infection but progress faster to AIDS for a given viral load than men [2] [3] [4] [5] [6] [7] . Here we show substantial sex differences in the response of plasmacytoid dendritic cells (pDCs) to HIV-1. pDCs derived from women produce markedly more interferon-a (IFN-a) in response to HIV-1-encoded Toll-like receptor 7 (TLR7) ligands than pDCs derived from men, resulting in stronger secondary activation of CD8 + T cells. In line with these in vitro studies, treatment-naive women chronically infected with HIV-1 had considerably higher levels of CD8 + T cell activation than men after adjusting for viral load. These data show that sex differences in TLRmediated activation of pDCs may account for higher immune activation in women compared to men at a given HIV-1 viral load and provide a mechanism by which the same level of viral replication might result in faster HIV-1 disease progression in women compared to men. Modulation of the TLR7 pathway in pDCs may therefore represent a new approach to reduce HIV-1-associated pathology.
According to UNAIDS, almost half of all HIV-1-infected individuals worldwide are women. Studies comparing the course of HIV-1 infection between women and men have demonstrated considerable sex differences in the manifestations of HIV-1 disease. Whereas HIV-1-infected women present with lower viral load early in HIV-1 infection, women with the same HIV-1 viral load as men have a 1.6-fold higher risk of developing AIDS [2] [3] [4] [5] [6] [7] . The mechanisms underlying these major sex differences in the manifestation of HIV-1 disease are not understood.
There is increasing consensus that the degree of immune activation in HIV-1-infected subjects is a strong independent predictor for HIV-1 disease progression [8] [9] [10] [11] [12] [13] [14] [15] [16] . pDCs have a central role in this HIV-1-induced activation of the immune system, as they can sense HIV-1 single-stranded RNA via TLR7 (refs. 17-20) . Notably, peripheral blood mononuclear cells (PBMCs) derived from women have been shown to produce markedly more IFN-a in response to the synthetic TLR7 ligand imiquimod than PBMCs derived from men 21 . We, therefore, reasoned that sex differences in HIV-1-induced immune activation might be responsible for the observed differences in HIV-1 disease and investigated differences in cytokine production by PBMCs in response to HIV-1 between men and women, as well as the consequences for T cell activation.
We used intracellular cytokine staining (ICS) by multiparameter flow cytometry to quantify the percentage of pDCs producing IFN-a or tumor necrosis factor-a (TNF-a) after stimulation with HIV-1-derived TLR7 and TLR8 (TLR7/8) ligands, TLR9 ligand ODN2216 (CpG-A) or aldrithiol-2-inactivated HIV-1 virus (AT-2 virus) (Fig. 1) . A significantly higher percentage of pDCs derived from women produced IFN-a in response to HIV-1-derived TLR ligands or AT-2 virus as compared to pDCs derived from men ( Fig. 1a-c) . In line with previous reports 21 , we detected no significant sex difference in the percentage of IFN-a-producing pDCs in response to the TLR9 ligand (Fig. 1a,b) . In contrast to the differences in IFN-a production by pDCs, the mean percentage of pDCs responding with TNF-a-production to stimulation with HIV-1-derived TLR7/8 ligands, although slightly higher, did not significantly differ between women and men ( Fig. 1d,e) , suggesting that the differences in cytokine production that we observed were mediated by a signaling event downstream of TLR7. The sex differences in IFN-a-producing pDCs were not due to differences between the studied men and women in race or ethnicity, the frequencies of described polymorphisms within the genes encoding TLR7, myeloid differentiation factor-88 (MyD88) and interferon regulatory factor-7 (IRF-7) or pDC numbers (data not shown). Furthermore, neither HIV-1-induced cytokine production by myeloid dendritic cells (mDCs) nor that by monocytes differed between women and men (P 4 0.4 for all comparisons). In summary, these data demonstrate major sex differences in the IFN-a pDC response to HIV-1-encoded TLR7/8 ligands and inactivated HIV-1.
Progestin has recently been shown to modulate pDC function in vitro 22 , suggesting that pDC function may be modulated by sex hormones. In our study, IFN-a production by pDCs in response to HIV-1-encoded TLR7/8ligands did not differ between women who reported the use of oral contraceptives and those who did not (P ¼ 0.79, data not shown). However, plasma progesterone concentrations significantly correlated with the percentage of IFN-a + pDCs after stimulation with the HIV-1-derived TLR7/8 ligand Gag RNA1166 (Fig. 2 , R ¼ 0.57, P ¼ 0.02). Furthermore, there was a trend toward lower percentages of IFN-a-producing pDCs in response to TLR7/8 ligands in postmenopausal women compared to premenopausal women (mean 16.9% versus 27.6%, P ¼ 0.08, data not shown), overall suggesting that sex hormone abundance can modulate the ability of pDCs to produce IFN-a in response to TLR7 stimulation.
IFN-a is a central cytokine in activating an antiviral immune response, and high circulating amounts of IFN-a are a major prognostic indicator for HIV-1 clinical progression 8, [23] [24] [25] . Furthermore, IFN-a has been shown in vitro to induce upregulation of CD38 on CD8 + T cells 26 , a strong independent predictor of HIV-1 disease progression [8] [9] [10] . In line with these observations, CD8 + T cells significantly upregulated CD38 expression after stimulation of PBMCs with HIV-1-derived TLR7/8 ligands or AT-2 virus in vitro (P o 0.001, Fig. 3a) . Furthermore, the expression of CD38 on CD8 + T cells after incubation with HIV-1-encoded TLR7/8 ligands and AT-2 virus was higher in women compared to men (Fig. 3b) . This in vitro activation of CD8 + T cells was at least partially mediated by IFN-a (Fig. 3c,d ). On the basis of these data demonstrating sex differences in HIV-1-induced immune activation in vitro, we hypothesized that treatment-naive, chronically HIV-1-infected women will show higher levels of CD8 + T cell activation than men with comparable HIV-1 viral loads.
To test this hypothesis, we quantified ex vivo T cell activation on pretreatment samples from chronically HIV-1-infected subjects enrolled into the AIDS Clinical Trials Group (ACTG) 384 study, including 109 treatment-naive women and 514 treatment-naive men 27, 28 . In ACTG 384, women had higher CD4 + T cell counts (340 versus 273 cells per mm 3 , P ¼ 0.002) and lower plasma HIV-1 RNA copy numbers (4.7 versus 5.0 log 10 copies per ml, P o 0.001) at enrollment, before initiation of antiretroviral therapy 27 . In line with previous reports, the degree of immune activation, defined by the percentage of CD38 + human leukocyte antigen (HLA)-DR + CD8 + T cells, was significantly associated with HIV-1 viral load at baseline (R ¼ 0.24, P o 0.001) but did not significantly differ between women and men at baseline (Fig. 4) . However, after adjusting for baseline HIV-1 viral load, the percentage of CD38 + HLA-DR + CD8 + T cells, but not CD38 + HLA-DR + CD4 + T cells, was significantly higher in women compared to men (P ¼ 0.28 for CD4 + T cells, Fig. 4a ; and P ¼ 0.006 for CD8 + T cells, Fig. 4b ). When ethnicity or intravenous drug use were included into the model, CD8 + T cell activation remained significantly higher in women compared to men after adjusting for HIV-1 viral load (P ¼ 0.004, data not shown). The higher CD8 + T cell activation in women compared to men (an average of 4.6% more CD38 + HLA-DR + CD8 + T cells) corresponds to the effect of approximately one log 10 higher plasma HIV-1 RNA copy numbers (Fig. 4b) . These in vivo data are consistent with the in vitro studies shown above (Fig. 1b) in which significant differences in immune activation mediated by sex differences in the pDC response to HIV-1 singlestranded RNA-encoded TLR7 ligands were observed and provide a mechanism by which the same HIV-1 viral load can result in higher immune activation and faster progression to AIDS 3, 29 in women compared to men. The expression of immune activation markers such as HLA-DR or CD38 on CD8 + T cells has been shown to independently predict the rate of HIV-1 disease progression [8] [9] [10] 30, 31 . The stimulation of the innate immune system, and, in particular, the chronic production of IFN-a, has been suggested to have a crucial role in driving this generalized immune activation and disease progression in HIV-1-infected individuals 16, 18, 23, 24, [32] [33] [34] . Furthermore, IFN-a has been suggested to be a key mediator for SIV pathogenesis in rhesus macaques 35, 36 , where pDCs from rhesus macaques, similarly to pDCs in humans, produce large amounts of IFN-a when stimulated with SIV or HIV-1. In contrast, sooty mangabeys, the natural hosts of SIV that do not progress to AIDS 37 , have markedly lower levels of T cell activation in chronic SIV infection, and pDCs of sooty mangabeys have been reported to produce less IFN-a in response to SIV 35 . These data suggest that persistent IFN-a production by pDCs in response to SIV or HIV-1 is a central factor in mediating virus-induced immune activation and the resulting pathogenesis in chronic infection. Major differences in the manifestations of HIV-1 disease have been previously reported between females and males, with women experiencing a substantially increased risk of developing AIDS compared to men for the same level of HIV-1 replication 2-7 . Here we show that treatment-naive women chronically infected with HIV-1 also have markedly higher levels of CD8 + T cell activation compared to men with the same HIV-1 viral load. In an attempt to elucidate a mechanism underlying this sex difference in the level of immune activation induced by similar amounts of HIV-1 RNA, we show that pDCs from women produce considerably higher amounts of proinflammatory IFN-a in response to HIV-1 than pDCs from men and that these higher levels of IFN-a secretion can lead to higher levels of CD8 + T cell activation. These data are consistent with a model in which higher TLR7-mediated responsiveness to HIV-1 RNA in women contributes to a more rapid HIV-1 disease progression in the presence of persistent chronic viral replication.
In conclusion, we demonstrate sex differences in the IFN-a production by pDCs after stimulation with HIV-1 single-stranded RNA that translate into enhanced CD8 + T cell activation in vitro and in vivo for the same amount of HIV-1 RNA in women compared to men. This enhanced immune activation in women can explain the previously reported clinical observation that women have a higher risk for HIV-1 disease progression then men during chronic infection at a given HIV-1 viral load. Modulation of the TLR7 pathways in pDCs could therefore represent a unique approach to reduce HIV-1-associated pathogenesis and might have implications that go beyond HIV-1 infection, as differential susceptibility to several RNA viruses have been described for men and women 1 , and autoimmune diseases that show sex differences in their incidence, such as systemic lupus erythematosus, have also been shown to involve the TLR7 and TLR8 pathway 38, 39 .
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ONLINE METHODS
Study subjects. The ACTG 384 study recruited 980 antiretroviral-naive HIV-1-infected subjects 28 . A subset of subjects (514 men and 109 women) followed at US sites underwent comprehensive immunologic assessments, which included the analysis of CD4 + and CD8 + T cell activation by flow cytometry. These included 287 white non-Hispanic individuals, 240 black non-Hispanic individuals, and 96 individuals with other backgrounds including Hispanics and those of Asian descent (all demographic information is as self-identified by the subjects). 578 of the 623 study subjects reported never using intravenous drugs, and 48 reported previous or current use of intravenous drugs. Furthermore, samples from 63 HIV-1-negative subjects enrolled at Massachusetts General Hospital were included in this study. Premenopausal women in the study were less than 40 years old, whereas the average age of postmenopausal women was 60 years. When available, we collected information on the use of oral contraceptives containing sex hormones, and 43% of premenopausal women reported the use of oral contraceptives. All subjects gave informed consent for participation in these studies. The study was approved by the Partners Institutional Review Board, and the ACTG 384 study was approved by local institutional review boards.
Analysis of polymorphisms within the genes encoding Toll-like receptor 7, myeloid differentiation factor-88 and interferon regulatory factor-7. We amplified the coding regions of the genes encoding MyD88 and IRF7 from genomic DNA with the primers listed in Supplementary Table 1 . In addition, we also amplified the genomic sequences flanking the TLR7 single nucleotide polymorphisms rs179008 and rs2302267 that have been implicated in HIV-1 and hepatitis C virus disease progression (see Supplementary Table 1 for primer sequences). Briefly, we amplified 10-20 ng of genomic DNA in 10-ml reactions (200 nm dNTPs, 1.5 mM MgCl 2 and 0.2 mM of each primer). We used a modified step-down program (annealing temperatures given in Supplementary Table 1 ) for amplification of the genes encoding IRF7 and MyD88 to ensure precise amplification. We amplified TLR7 single nucleotide polymorphisms at an annealing temperature of 55 1C. We subjected PCR products to direct bidirectional cycle sequencing using Bigdye terminator v. 1.1 run on an ABI3730 sequencer.
Measurement of single-cell cytokine production by flow cytometry. We stimulated 1.5 Â 10 6 PBMCs per ml with 15 mg ml À1 single-stranded RNA (sequences of HIV-1 single-stranded RNA, Gag RNA1166 (5¢-UUGUUAAGUGUU UCAAUUGU-3¢) and Gp160 RNA2093 (5¢-UUUUUGCUGUACUUUCUAUA-3¢)) complexed with DOTAP transfection reagent (Roche), 1 mg ml À1 CL097 (Invivogen) or 5 mM ODN2216 (Invivogen). We also stimulated cells with aldrithiol-2-inactivated HIV-1 virus (AT-2, MN strain, lot P4097) and microvesicle controls (lot P4079; AIDS and Cancer Virus Program, Science Applications International Corporation Frederick, Inc., National Cancer Institute, Frederick). Unstimulated cells served as negative controls. We immediately added 5 mg ml À1 brefeldin A (Sigma) to each tube after adding TLR ligands to inhibit cellular cytokine release. We determined the intracellular cytokine content of monocytes, mDCs and pDCs after 20 h of incubation with the respective TLR ligands, as described previously 20 . We acquired all samples on an LSR II flow cytometer (BD Biosciences). We determined the percentage of cytokineproducing pDCs, mDCs and monocytes by subsequent analysis with FlowJo software (Treestar, Inc.). An average of 92% of lin neg CD11c neg CD123 bright IFN-a + pDCs also expressed CD303 (blood dendritic cell antigen-2) (data not shown).
Measurement of in vitro T cell activation in HIV-1-negative men and women. We performed flow cytometric quantification of CD38 high CD4 + and CD38 high CD8 + T cells on freshly isolated PBMCs from healthy HIV-1-negative control individuals after stimulation with HIV-1-derived single-stranded RNA ligands, vesicle control and AT-2 virus. For the in vitro IFN-a blocking assays, we pretreated PBMCs from HIV-1-negative individuals with antibodies directed against IFN-a receptor 1 and IFN-a receptor 2 (Abcam and PBL Interferonsource, respectively) for 1 h at 37 1C. We then stimulated PBMCs with a TLR7/8 ligand (CL097 at 1 mg ml À1 ) or with medium alone for 20 h. Furthermore, we stimulated PBMCs in vitro with increasing amounts of recombinant human IFN-a (1-100 ng ml À1 ) for 20 h, and we measured T cell activation as described above.
Measurement of ex vivo T cell activation in HIV-1-infected men and women enrolled in ACTG 384. We quantified CD4 + and CD8 + T cell activation by flow cytometry of freshly isolated PBMCs from study participants at baseline, before the initiation of antiretroviral therapy, according to established ACTG protocols. We defined activated CD4 + and CD8 + T cells by their expression of either CD4 or CD8 and their expression of CD38 and HLA-DR. Results are reported as the percentage of CD38 + HLA-DR + CD4 + T cells or percentage of CD38 + HLA-DR + CD8 + T cells.
Statistical analyses. For the immunologic assays on HIV-1-negative individuals, we used two-tailed Student's t-tests and Wilcoxon rank tests (MannWhitney or Wilcoxon signed-rank test for paired samples) to determine statistically significant differences. For the ACTG study, we compared continuous outcomes between men and women with Wilcoxon rank-sum tests. We used rank-based (Spearman) correlations to assess association between responses. We used multiple regression models to assess the association between activation percentage and sex, adjusting for HIV-1 viral load. All statistical tests were two-sided exploratory tests without adjustments for multiple testing at the 5% nominal level of significance.
